Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Myriad Genetics to Split Pharma From Dx Business, Creating New Drug Company
October 22, 2008
Myriad Genetics’ board of directors has unanimously approved a plan to spin off the company’s research and drug development business from its core diagnostics business. The parent company is eyeing new acquisitions for the diagnostics firm and plans to infuse the fledgling drug company with enough cash to help it through at least two products submissions to the US Food and Drug Administration.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Firefly Nets $500K Grant from Massachusetts Life Sciences Center
May 23, 2012 / GenomeWeb Daily News - NIH Awards Lucigen $2.8M SBIR Grant for POC Influenza Test
May 23, 2012 / GenomeWeb Daily News - Genentech Takes Personalized Medicine Approach in Pursuing Amyloid Hypothesis for Alzheimer's Drug
May 23, 2012 / Pharmacogenomics Reporter - Agilent to Strengthen Personalized Rx Foothold with $2.2B Dako Acquisition
May 23, 2012 / Pharmacogenomics Reporter - NIH Study Finds DTC Genetic Risk Info Doesn't Increase Patients' Use of Healthcare Services
May 23, 2012 / Pharmacogenomics Reporter